Board

Mr Phillip Lynch

Executive Chair 

Mr Lynch is an experienced executive and director. He is the Independent Chair at Consumer Healthcare Products Australia, and previously served as Non-Executive Director at Race Oncology (ASX:RAC), after having also held the position of CEO and Managing Director.

Prior to this, Mr Lynch spent more than 30 years with Johnson & Johnson in senior roles across the Asia Pacific region, where he gained expertise in corporate development, strategy, financial performance, marketing and governance. 

Dr David Foster

Managing Director 

Dr Foster has 20+ years experience in life sciences representing pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice.

He served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb.

Dr Foster co-founded Roberts Foster LLP - a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies.

He is a board member of bionorthTx and private biotechnology companies, and is a Member of Australian Institute of Company Directors.

He holds a Ph.D. from The University of Texas Southwestern Medical Center and J.D. from Golden Gate University School of Law.

Mr Albert Hansen

Non-Executive Director 

Mr Al Hansen is the Managing Partner. KESA Partners. He brings decades of experience in healthcare and investment, including Managing Director of Signet Healthcare Partners, serving on investee companies as Chairman, Director and Interim CEO of pharmaceutical companies and CROs.

Mr Hansen has substantial senior investment banking experience at firms such as Darby Overseas Investments, Dillon Read and E. F. Hutton. Former Director - Corporate Finance US Treasury, and retired Captain, U.S Army Special Forces.

Mr Chris Ntoumenopoulos

Non-Executive Director 

Mr Chris Ntoumenopoulos has more than 20 years’ financial markets experience and is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. 
 
He was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a Non-Executive Director at TrivarX Limited (ASX:TRI) and Tryp Therapeutics (ASX: TYP).